Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 179

Registration Number: NCT00003650

Locations: 🇫🇷
Centre Leon Berard, Lyon, France

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 400

Registration Number: NCT00003215

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease

Phase 3

Completed

Conditions: Graft Versus Host Disease

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00043147

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cyclosporine
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: mercaptopurine
Drug: methotrexate
Drug: methylprednisolone
Drug: pegaspargase
Drug: thioguanine
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-20

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 6

Registration Number: NCT00022126

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States

and more 48 locations

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Daclizumab
Drug: Methylprednisolone
Drug: Placebo
Drug: Mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2002-10-25

Last Posted Date: 2016-06-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 434

Registration Number: NCT00048165

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Phase 4

Withdrawn

Conditions: Demyelinating Disorders
Multiple Sclerosis
Optic Neuritis
Myelitis
Neuritis

First Posted Date: 2002-05-17

Last Posted Date: 2018-04-12

Lead Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute

Registration Number: NCT00037115

Locations: 🇺🇸
MidAmerica Neuroscience Institute, Kansas City, Missouri, United States

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

Phase 3

Withdrawn

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000741

Locations: 🇺🇸
Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸
Duke Univ Med Ctr, Durham, North Carolina, United States

and more 3 locations

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Phase 2

Terminated

Conditions: End-Stage Renal Disease

Interventions: Drug: Basiliximab
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Sirolimus
Drug: Methylprednisolone
Drug: Prednisone
Drug: Bactrim

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 274

Registration Number: NCT00023244

Locations: 🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸
The Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸
Westchester Medical Center, Valhalla, New York, United States

and more 16 locations

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

Phase 3

Terminated

Conditions: HIV Infections
Pneumonia, Pneumocystis Carinii

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT00000730

Locations: 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2001-06-06

Last Posted Date: 2005-06-24

Lead Sponsor: Northwestern Memorial Hospital

Target Recruit Count: 20

Registration Number: NCT00017628

Locations: 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy